SCOHIA PHARMA, Inc.
November 28, 2019

SCOHIA initiates a phase 2 proof of concept study of an enteropeptidase inhibitor (SCO-792) in type 2 diabetes mellitus patients with obesity.

SCOHIA PHARMA, Inc. today announced that an enteropeptidase inhibitor (SCO-792) has progressed into a phase 2 proof of concept study in type 2 diabetes mellitus patients with obesity.

This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study conducted to evaluate the safety and efficacy of SCO-792 in approximately 100 type 2 diabetes mellitus patients with obesity in Australia and New Zealand.

For more information about the study, visit the following website.
https://www.clinicaltrials.jp/cti-user/trial/Search.jsp
(Please search by JapicCTI-194848).

[About enteropeptidase inhibitor (SCO-792)]
SCO-792 is one of the in-licensed compounds from Takeda Pharmaceutical Company Limited. This compound is expected to be a first-in-class oral drug for treating type 2 diabetes mellitus and obesity with a completely novel mechanism of action. It inhibits enteropeptidase, which is localized in the intestine and involved in the digestion of proteins in meals, exhibiting a similar effect as that of bariatric surgery performed in patients with advanced obesity. A phase 1, randomized, double-blind, comparative study has demonstrated that SCO-792 is safe and well tolerated in healthy adults, wherein its pharmacological effects were also exhibited through inhibition of enteropeptidase activity. Our company has presented papers on preclinical studies and compound profiles of SCO-792.

[About SCOHIA PHARMA, Inc.]

SCOHIA PHARMA, Inc. is a drug discovery bioventure focusing on the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit https://www.scohia.com/eng/.